Diagnostic Value of Serum MIF and CCL23 in the Patients with Acute Cerebral Infarction

Wang, Xinxin; Yang, Yonghong; Zhao, Zonggang; Ma, Caihong; Zhu, Baike

doi:10.7754/clin.lab.2020.200239

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The activation of macrophages, frequently reflected by an increase in ferritin, was suggested as one of the major drivers of COVID-19 evolution and was related to the degree of neuronal degeneration and injury in general [ 26 , 83 , 122 , 125 , 128 , 129 , 130 ]. Elevations in CCL23, a cytokine involved in the recruitment of leukocytes to nervous system compartments and linked to vascular injury-related stroke, could suggest an influx of peripheral leukocytes into the brain [ 68 , 69 , 70 ]. Our study is correlational; however, several other investigations suggest that ongoing neuroinflammation leads to neurodegeneration [ 10 , 51 , 59 , 65 , 80 , 85 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the influx of peripheral leukocytes into the central nervous system via a dysfunctional BBB can fuel neuroinflammation [ 65 , 66 , 67 ]. Monocyte chemoattractant proteins (MCP), monocyte inhibitory factor (MIF), C-X-C motif ligand 13 (CXCL13), and C-C motif ligand 23 (CCL23), have been implicated in intraparenchymal leukocyte migration, vasculitis and, in the case of CCL23, MIF, and MCP-1, are linked to the progression of dementia by supporting chronic neuroinflammation [ 68 , 69 , 70 , 71 , 72 , 73 , 74 ]. Concomitantly, the radiographic indicators of neuronal damage and vascular injury persist for three months after the resolution of COVID-19 [ 75 , 76 , 77 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes

et al. 2021

View full text Add to dashboard Cite

The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinflammatory (MIF, CCL23, MCP-1), neuro-injury (NFL, NCAM-1), neurodegenerative (KLK6, τ, phospho τ, amyloids, TDP43, YKL40), and neuroprotective (clusterin, fetuin, TREM-2) proteins. These were compared to markers of nonspecific inflammatory responses (IL-6, D-dimer, CRP) and of the overall viral burden (spike protein). Data regarding treatment (steroids, convalescent plasma, remdasavir), pre-existing conditions, and incidences of strokes were collected. Amyloid β42, TDP43, NF-L, and KLK6 serum levels declined 2–3 days post-admission, yet recovered to admission baseline levels by 7 days. YKL-40 and NCAM-1 levels remained elevated over time, with clusters of differential responses identified among TREM-2, TDP43, and YKL40. Fetuin was elevated after the onset of COVID-19 while TREM-2 initially declined before significantly increasing over time. MIF serum level was increased 3–7 days after admission. Ferritin correlated with TDP-43 and KLK6. No treatment with remdesivir coincided with elevations in Amyloid-β40. A lack of convalescent plasma resulted in increased NCAM-1 and total tau, and steroidal treatments did not significantly affect any markers. A total of 11 incidences of stroke were registered up to six months after initial admission for COVID-19. Elevated D-dimer, platelet counts, IL-6, and leukopenia were observed. Variable MIF serum levels differentiated patients with CVA from those who did not have a stroke during the acute phase of COVID-19. This study demonstrated concomitant and opposite changes in neurodegenerative and neuroprotective markers persisting well into recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Результаты настоящего исследования демонстрируют непосредственную связь между повышением концентрации MPIF-1/CCL23 и снижением повседневной активности и уровня независимости по шкалам mRS, BI у пациентов с умеренной тяжестью ИИ. Полученные результаты согласуются с данными исследований, демонстрирующих положительную корреляцию экспрессии MPIF-1/CCL23 с показателями NIHSS и отрицательную с показателями BI, что позволяет рассматривать данный хемокин в качестве инструмента прогнозирования функционального исхода у пациентов с ишемическим инсультом [38,39].…”

Section: Discussionunclassified

Linking Immunological Parameters and Recovery of Patient’s Motor and Cognitive Functions In The Acute Period of Ischemic Stroke

Tynterova,

Shusharina,

Golubev

et al. 2024

Obŝaâ reanimatologiâ

View full text Add to dashboard Cite

Objective. To evaluate the relationship between immunological parameters and functional outcome in patients with varying severity of ischemic stroke based on statistical methodology.Materials and methods. The prospective study included 78 patients diagnosed with ischemic stroke, who were distributed into two groups: group 1 — 38 mild stroke patients, NIHSS score < 5, group 2 — 40 moderate stroke patients, NIHSS score 5–15. Signs of stroke severity, degree of disability, cognitive decline, and activities of daily living were chosen as criteria to estimate the functional outcome by calculating the difference between the NIHSS, mRS, MoCA, and BI scales at the time of admission and on Day 12 of hospital stay. Lab tests included assessment of plasma concentrations of CXC and CC subfamilies of cytokines, interleukins and TNF-a on Day 2 of hospital stay. Machine learning algorithms, the Python programming language, the Pandas and SciPy libraries, and discriminant analysis were used for statistical processing.Results. The following parameters were found as significant: concentrations of IL-1b and MPIF-1/CCL23 for — for group 1, and concentrations of IL-16, MPIF-1/CCL23, Eotaxin-2/CCL24, Gro-a/CXCL1 and IL-8/CXCL8 for group 2 patients. Positive correlation was established between NIHSS dynamics and concentrations of TNF-a (R=0.227, P=0.001), MPIF-1/CCL23 (R=0.380, P=0.00061) and Gro-a/CXCL1 (R=0.211, P=0.00001), and between changes in mRS and concentrations of MPIF-1/CCL23 (R=0.277, P=0.00006), Gro-a/CXCL1 (R=0.211, P=0.0075) and IL-16 (R=0, 211, P=0.00001). There was a significant negative correlation between cognitive dysfunction and concentrations of Eotaxin-2/CCL24 (R=–0.378, P=0.00075), Gro-a/CXCL1 (R=–0.313, P=0.0035), and IP-10/CXCL1 (R=–0.214, P=0.00023), and between limited activities of daily living (IB) and concentrations of MPIF-1/CCL23 (R=–0.345, P=0.0024) and Gro-a/CXCL1 (R=–0.210, P=0.00001).Conclusion. Chemokines form the CC family — MPIF-1/CCL23 and Eotaxin-2/CCL24, and the CXC-Gro-a/CXCL1 and IL-16 clusters are the principal cytokines associated with the dynamics of patient’s motor and cognitive functions recovery in the acute period of ischemic stroke. Although obtained results demonstrate negative effect of increased MPIF-1/CCL23, Gro-a/CXCL1, IL-16 and Eotaxin-2/CCL24 concentrations on the improvement of motor and cognitive impairments, further studies are needed to verify the CXC and CC subfamilies chemokines as prognostic markers of patient’s functional outcome in the acute period of ischemic stroke.

show abstract

“…Serum CCL23 has been implicated in multiple inflammatory diseases, such as systemic sclerosis, chronic rhinosinusitis, chronic kidney disease, and atherosclerotic disease [ 18 , 24 , 25 , 26 ]. Notably, CCL23 is also involved in the inflammatory response of brain injury and serves as a prognostic biomarker of Alzheimer’s disease and cerebral ischemia [ 27 , 28 , 29 ]. Here, we proposed that CCL23 might have a role in the inflammation of aSAH.…”

Section: Introductionmentioning

confidence: 99%

Elevated Serum CCL23 Levels at Admission Predict Delayed Cerebral Ischemia and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage

Lin

Shen

Zhu

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: CC chemokine ligand 23 (CCL23) is a chemokine implicated in the inflammatory response following brain damage. The aim of this study is to identify the change in serum CCL23 levels within 24 h after aSAH and whether serum CCL23 levels are associated with initial clinical severity, delayed cerebral ischemia (DCI), and functional outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). (2) Methods: 102 patients with aSAH and 61 controls were included in this prospective observational study. All clinical data were collected prospectively, and their serum CCL23 levels were measured. Initial clinical severity was reflected by the Hunt–Hess score and mFisher score. Functional outcome was evaluated in terms of the Glasgow Outcome Scale (GOS) score at 6-month follow-up. (3) Results: Patients with aSAH had higher serum CCL23 levels than controls. The temporal profile of serum CCL23 levels and neutrophils count exhibited a sustained increase within 24 h after aSAH. Serum CCL23 levels were related to blood neutrophils count, blood CRP levels, and initial clinical severity. Serum CCL23 level was an independent predictor of DCI and 6-month poor outcome in aSAH patients. (4) Conclusions: Serum CCL23 levels emerged as an independent predictor for DCI and poor outcome in patients with aSAH.

show abstract

Diagnostic Value of Serum MIF and CCL23 in the Patients with Acute Cerebral Infarction

Cited by 5 publications

References 0 publications

Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes

Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes

Linking Immunological Parameters and Recovery of Patient’s Motor and Cognitive Functions In The Acute Period of Ischemic Stroke

Elevated Serum CCL23 Levels at Admission Predict Delayed Cerebral Ischemia and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage

Contact Info

Product

Resources

About